e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment
C. Navarro, M. Perez, D. Hernandez, E. Ansotegui, M. Cebrian, J. Peman, A. Sole (Valencia, Spain)
Source:
Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Session:
Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Session type:
Poster Discussion
Number:
3380
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Navarro, M. Perez, D. Hernandez, E. Ansotegui, M. Cebrian, J. Peman, A. Sole (Valencia, Spain). Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment. Eur Respir J 2012; 40: Suppl. 56, 3380
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Allergic bronchopulmonary aspergillosis and other fungal diseases
Source: Eur Respir Mon 2011; 52: 97-114
Year: 2011
Diagnostic value of combined sIgG and sIgE of Aspergillus fumigatus in allergic broncho pulmonary aspergillosis and severe asthma with fungal sensitation
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Peripheral blood eosinophilia and sensitization to Aspergillus fumigatus in adult patients (pts) with non-cystic fibrosis bronchiectasis (B)
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Elevated CEA levels in sera in patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2011 - Biomarkers of allergic inflammation
Year: 2011
IgE expression in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2013 –Asthma
Year: 2013
Allergic bronchopulmonary aspergillosis (ABPA) by
Aspergillus flavus
Source: Eur Respir J 2001; 18: Suppl. 33, 218s
Year: 2001
Complex treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthmatic patient including anti-IgE therapy – A case report
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012
Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Follow-up of patients with allergic bronchopulmonary aspergillosis (ABPA) - side effects of long-term therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 237s
Year: 2003
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis
Source: Eur Respir J 2003 Oct 01;22(4):592-595
Year: 2003
Analogs of Asp f 1 (αsarcin, mitogillin and restrictocin) on the diagnosis and stage assessment of allergic bronchopulmonary aspergillosis
Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond
Year: 2008
Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2008; 31: 36-42
Year: 2008
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Bronchopulmonary aspergillosis
Source: Respipedia Article
Year: 2017
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Prevalence of possible severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) in a UK secondary care hospital
Source: Annual Congress 2013 –Epidemiology of asthma
Year: 2013
Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept